Skip to main content
Pear Therapeutics

Magellan Health Continues Innovation and Efforts to Improve Outcomes for Patients with Substance Use Disorder

By January 17, 2018No Comments

Magellan Health, Inc. (NASDAQ: MGLN) has long been the national leader in the use of digital innovation to help those struggling with various medical and behavioral conditions, including Substance Use Disorders (SUD). As a pioneer in the use of digital therapeutics and computerized cognitive behavioral therapy (CCBT), Magellan has engaged in a new initiative designed to measure clinical outcomes in patients with SUD by leveraging reSET®, the first ever FDA cleared prescription digital therapeutic from PEAR Therapeutics.